Patients with relapsed/refractory multiple myeloma could benefit from repeat treatment with drugs their disease has ...

The suitability of Kasiya coarse flake graphite for use in traditional refractory and foundry applications grants Sovereign ...

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI® reduced the risk of disease progression or death by 74 per cent compared to ...

C3N4 photocatalyst modified with atomically dispersed Fe (Fe1/OPCN) with significant superiority in removing refractory ...

Please note that following on from information provided to NICE by the company in July 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from ...

Omega Therapeutics is halting work on its only clinical-stage candidate as part of a strategic refocus centered on three ...

It is a possible treatment for multiple myeloma in adults that has come back (relapsed) or stopped responding to treatment (refractory). It can only be ... moving to alternatives if the first does not ...

Haduvio, which operates both centrally and peripherally, is expected to serve a wider patient base compared to potential competitors like GSK’s camplipixant, which does not work for a significant ...

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal ...

Beck’s, the largest family-owned retail seed company in the United States, will establish a new soybean processing facility ...

Q3 2024 Earnings Call Transcript November 14, 2024 Affimed N.V. beats earnings expectations. Reported EPS is $-1.03, ...

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers ...